Rafael Amado
2020 - Allogene Therapeutics
In 2020, Rafael Amado earned a total compensation of $2.7M as Chief Medical Officer and Executive Vice President of Research and Development at Allogene Therapeutics, a 64% decrease compared to previous year.
Compensation breakdown
| Bonus | $75,000 |
|---|---|
| Non-Equity Incentive Plan | $255,000 |
| Option Awards | $1,262,643 |
| Salary | $510,000 |
| Stock Awards | $561,176 |
| Total | $2,663,819 |
Amado received $1.3M in option awards, accounting for 47% of the total pay in 2020.
Amado also received $75K in bonus, $255K in non-equity incentive plan, $510K in salary and $561.2K in stock awards.
Rankings
In 2020, Rafael Amado's compensation ranked 4,310th out of 13,090 executives tracked by ExecPay. In other words, Amado earned more than 67.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,310 out of 13,090 | 67th |
Division Manufacturing | 1,743 out of 5,624 | 69th |
Major group Chemicals And Allied Products | 680 out of 2,257 | 70th |
Industry group Drugs | 581 out of 1,957 | 70th |
Industry Biological Products, Except Diagnostic Substances | 135 out of 411 | 67th |
Source: SEC filing on April 22, 2021.
Amado's colleagues
We found four more compensation records of executives who worked with Rafael Amado at Allogene Therapeutics in 2020.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Adaptimmune Therapeutics CEO James Noble's 2018 pay jumps 58% to $2.6M
March 15, 2019